
|Videos|February 14, 2014
Pazopanib for the Treatment of Soft Tissue Sarcoma
Author(s)Vicki Keedy, MD
Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses pazopanib for the treatment of soft tissue sarcoma.
Advertisement
Clinical Pearls
Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses pazopanib for the treatment of soft tissue sarcoma.
- Pazopanib was recently approved for the treatment of patients with advanced soft tissue sarcoma who have received prior chemotherapy
- Treatment with pazopanib quadrupled progression-free survival compared with placebo
- Drugs to treat soft tissue sarcoma are generally toxic
- Pazopanib is well tolerated, with some instances of extended fatigue
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5







































